- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07613996
Impact of Hyperemic State on Angio-IMR Performance
The Impact of Hyperemic State on the Performance of Angiography Derived Indices in Assessing Coronary Microvascular Disease
The goal of this observational study is to evaluate the diagnostic performance of angiography-derived microcirculatory indices (Angio-IMR) in assessing patients with stable angina or suspected coronary artery disease. The main questions it aims to answer are:
How do the numerical values of Angio-IMR from five different software vendors change across three physiological states (resting, sub-hyperemia induced by nitroglycerin, and maximal hyperemia induced by adenosine)? Which physiological state and software algorithm provide the highest diagnostic accuracy (Area Under the Curve, AUC) for diagnosing Coronary Microvascular Disease (CMD) when compared to the gold standard wire-based IMR? Researchers will compare the Angio-IMR results calculated under the three different physiological conditions within the same patient to see how the hyperemic state impacts the performance and consistency of these non-invasive indices.
Participants will:
Undergo standard-of-care coronary angiography and physiological assessment using a pressure wire for index of microvascular resistance (Wire-IMR) as part of their clinical management.
Have their angiographic images captured at three specific time points: at rest, after intracoronary nitroglycerin, and during adenosine-induced maximal hyperemia.
Allow their de-identified imaging and clinical data to be analyzed by an independent core laboratory using five different Angio-IMR software platforms to evaluate microvascular function.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Study Overview and Procedural Protocol
This is a prospective, multi-center, diagnostic accuracy study employing a self-controlled design. All participants will undergo coronary angiography and physiological assessment according to standard clinical indications. During the procedure, specific angiographic images will be systematically captured for the target vessel at three distinct physiological time points:
Resting State: Baseline coronary angiography without any hyperemic agents. Sub-hyperemic State: Following the intracoronary administration of nitroglycerin.
Maximal Hyperemic State: During continuous intracoronary infusion of adenosine to achieve maximal microvascular vasodilation.
Immediately following image acquisition, the reference standard measurement-Wire-IMR-will be performed using a pressure-sensor-equipped guidewire under maximal hyperemia.
Core Laboratory Imaging Analysis and Blinding
All angiographic data will be de-identified and transferred to a centralized, independent Cardiovascular Imaging Core Laboratory at Zhongshan Hospital, Fudan University. The analysis will be conducted as follows:
Software Platforms: Five different commercially available Angio-IMR software platforms (anonymized as A, B, C, D, and E) will be used to calculate microvascular resistance.
Independent Analysis: Five dedicated analysts, each specialized in one specific software platform, will perform the calculations. Each analyst will be blinded to the patients' clinical information, the Wire-IMR gold standard results, and the results from the other four software platforms.
Standardization: A primary researcher, not involved in the software measurements, will pre-define the target vessel segments and measurement frames to ensure consistency across all five software platforms.
Statistical Considerations and Data Management The study aims to determine if the coronary hyperemic state significantly alters the fluid dynamics modeling utilized by Angio-IMR algorithms. AUC will be calculated for each software at each of the three states. A head-to-head comparison of AUCs will be performed using DeLong's test. To maintain data integrity, results from the core laboratory and the clinical centers will remain strictly separated until the final database lock.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Jinying Zhou, MD, PhD
- E-mail: zhou.jinying@zs-hospital.sh.cn
Undersøgelse Kontakt Backup
- Navn: Chenguang Li, MD, PhD
- Telefonnummer: 021 6404 1990
- E-mail: li.chenguang@zs-hospital.sh.cn
Studiesteder
-
-
-
Guangzhou, Kina
- Rekruttering
- The First Affiliated Hospital, Sun Yat-sen University
-
Kontakt:
- Xun Hu, MD, PhD
- Telefonnummer: 020-87608185
- E-mail: hxun@mail.sysu.edu.cn
-
-
Please Select
-
Shanghai, Please Select, Kina, 200000
- Rekruttering
- Zhongshan Hospital, Fudan University
-
Kontakt:
- Jinying Zhou, MD, PhD
- Telefonnummer: 021 6404 1990
- E-mail: zhou.jinying@zs-hospital.sh.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
The study population consists of adult patients (aged 18 and older) clinically diagnosed with stable angina or suspected coronary artery disease who are scheduled to undergo conventional coronary angiography and invasive physiological assessment.
Participants are prospectively and consecutively recruited from multiple clinical centers in China. The population specifically targets individuals with non-obstructive coronary arteries (stenosis < 50%) or those with moderate stenosis (50%-90%) but preserved epicardial flow (FFR > 0.80), where assessment of coronary microvascular function is clinically indicated to investigate the cause of ischemia.
Beskrivelse
Inclusion Criteria:
- Stable angina or suspected coronary heart disease.
- Scheduled for coronary angiography and physiological assessment.
- Target vessel with stenosis < 50% or 50%-90% with fractional flow reserve (FFR) > 0.80.
- Provided informed consent.
Exclusion Criteria:
- Hemodynamic instability (acute myocardial infarction, cardiogenic shock, severe arrhythmia).
- Contraindications to angiography (e.g., end-stage renal disease).
- Contraindications to adenosine (e.g., severe asthma, high-degree atrial-ventricular block).
- Life expectancy < 1 year or pregnancy.
- Target vessel unsuitable for wire operation (left main lesion, severe tortuosity) or stenosis > 90%.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Single cohort, self-controlled
|
Unlike the reference standard "Wire-IMR," which requires the advancement of a specialized pressure-sensor guidewire into the distal coronary artery, Angio-IMR is a wire-free technology.
It derives microvascular resistance indices purely through computational fluid dynamics (CFD) or specialized mathematical models based on standard coronary angiographic projections.
This eliminates the risk of wire-induced vascular injury or spasm.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area Under the ROC Curve (AUC)
Tidsramme: Baseline
|
Comparison of AUC for 5 types of Angio-IMR against Wire-IMR (Gold standard, CMD defined as Wire-IMR ≥ 25) under three states.
|
Baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic Accuracy
Tidsramme: Baseline
|
Sensitivity, specificity, positive predictive value, negative predictive value.
|
Baseline
|
|
Correlation
Tidsramme: Baseline
|
Pearson/Spearman coefficients between Angio-IMR and Wire-IMR.
|
Baseline
|
|
Agreement
Tidsramme: Baseline
|
Bland-Altman analysis (Bias and Limits of Agreement).
|
Baseline
|
|
Inter-vendor Agreement
Tidsramme: Baseline
|
Consistency between different software brands.
|
Baseline
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- B2026-265
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Koronararteriesygdom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aorta origin of the coronary artery (AAOCA)Italien
-
University Hospital OstravaRekrutteringIn-Stent Carotis Artery RestenosisTjekkiet
-
Zhejiang Cancer HospitalRekrutteringHepatic Artery Infusion | Levermetastase fra BrystkræftKina
-
Sohag UniversityIkke rekrutterer endnuUmblical artery Doppler under terminsgraviditetEgypten
-
Nanfang Hospital, Southern Medical UniversityAfsluttetLeverskade | Hepatecellular carcinoma | HAIC (Hepatic Artery Infusion Chemotherapy) | TACE(Transkateter arteriel kemioembolisering)Kina
-
Inova Health Care ServicesBoston Scientific CorporationAfsluttetKoronar angiografi | Transradial adgang | Radial arterie Intimal Medial Tykkelse | Distal Radial Artery Access (dTRA)Forenede Stater
-
Baylor College of MedicineAfsluttetLungeblødning | MAPCA - Major Aortopulmonary Collateral ArteryForenede Stater
-
IRCCS Policlinico S. DonatoUniversity of Pavia; University of Naples; The Mediterranean Institute for...RekrutteringMyokardieiskæmi | Pludselig hjertedød | Anomal koronararterieoprindelse | Anomal koronararterie, der opstår fra den modsatte sinus | Anomal koronararterie med aorta-oprindelse og forløb mellem de store arterier | Anomalous aorta origin of the coronary artery (AAOCA) | Myokardieiskæmi, Angina Pectoris og andre forholdItalien
-
Daewoong Pharmaceutical Co. LTD.UkendtMCA - Middle Cerebral Artery DissektionKorea, Republikken
-
Nanfang Hospital, Southern Medical UniversityRekrutteringHepatocellulært karcinom (HCC) | Følelsesmæssig nød | Immunterapi | Målrettet terapi | HAIC (Hepatic Artery Infusion Chemotherapy)Kina
Kliniske forsøg med Angiography-derived IMR
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.Trukket tilbageHjertesvigt med bevaret ejektionsfraktion
-
Kimera Society IncAfsluttetKronisk obstruktiv lungesygdomForenede Stater
-
University Hospital, AkershusAfsluttetManiodepressiv | Psykose | Andre diagnoser og tilstandeNorge
-
Consorzio Futuro in RicercaAfsluttetIldfast Angina PectorisItalien
-
Jordan Collaborating Cardiology GroupAfsluttet
-
Imara, Inc.Aktiv, ikke rekrutterendeSeglcellesygdomForenede Stater, Det Forenede Kongerige
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.Afsluttetβ ThalassæmiIsrael, Frankrig, Malaysia, Kalkun, Danmark, Georgien, Grækenland, Italien, Libanon, Marokko, Holland, Tunesien, Det Forenede Kongerige
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.AfsluttetSeglcellesygdomForenede Stater, Oman, Italien, Det Forenede Kongerige, Libanon, Grækenland, Marokko, Tunesien, Ghana, Kenya, Holland, Senegal, Uganda
-
University of WashingtonAfsluttetSkizofreni | Maniodepressiv | Svær psykisk sygdom
-
Assistance Publique Hopitaux De MarseilleIkke rekrutterer endnu